scholarly journals Revisiting the Cutaneous Impact of Oral Hormone Replacement Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Gérald E. Piérard ◽  
Philippe Humbert ◽  
Enzo Berardesca ◽  
Ulysse Gaspard ◽  
Trinh Hermanns-Lê ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Hormone Therapy ◽  
Replacement Therapy ◽  
Aging Process ◽  
Hormone Replacement ◽  
Estrogen Therapy ◽  
Estrogen Deficiency ◽  
Hair Follicles ◽  
Menstrual Period ◽  
Transdermal Estrogen

Menopause is a key point moment in the specific aging process of women. It represents a universal evolution in life. Its initiation is defined by a 12-month amenorrhea following the ultimate menstrual period. It encompasses a series of different biologic and physiologic characteristics. This period of life appears to spot a decline in a series of skin functional performances initiating tissue atrophy, withering, and slackness. Any part of the skin is possibly altered, including the epidermis, dermis, hypodermis, and hair follicles. Hormone replacement therapy (oral and nonoral) and transdermal estrogen therapy represent possible specific managements for women engaged in the climacteric phase. All the current reports indicate that chronologic aging, climacteric estrogen deficiency, and adequate hormone therapy exert profound effects on various parts of the skin.

MENOPAUSAL HORMONOTHERAPY IN ONCOGYNECOLOGIC PATIENTS

2017 ◽  
Vol 63 (6) ◽  
pp. 843-854
Author(s):  
Olga Novikova ◽  
Yelena Ulrikh ◽  
V. Nosov ◽  
A. Charkhifalakyan
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Endometrial Cancer ◽  
Hormone Replacement Therapy ◽  
Hormone Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Menopausal Hormone Therapy ◽  
Oncological Safety

There is presented the review of domestic and foreign references on the conserved oncological safety of the use of menopausal hormone therapy after treatment for endometrial cancer, cervical cancer, borderline and malignant ovarian tumors, various variants of sarcomas of the uterus, vulva and vaginal cancer. To the opinion of the authors the refusal to prescribe menopausal hormone therapy to patients with oncogynecologic diseases in the anamnesis is usually not justified, the category of patients, to whom hormone replacement therapy is contraindicated, is well described and mentioned in the text. In other cases sex hormones can be used to treat menopausal symptoms and improve the quality of life of patients.

Hormone replacement therapy with estradiol and drospirenone: An overview of the clinical data

2006 ◽  
Vol 12 (1_suppl) ◽  
pp. 4-7 ◽  
Author(s):  
Malcolm Whitehead
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Density ◽  
Replacement Therapy ◽  
Endometrial Hyperplasia ◽  
Hormone Replacement ◽  
Estrogen Therapy ◽  
New Form ◽  
The Uk ◽  
Mineralocorticoid Activity ◽  
Synthetic Progestogen

A new form of continuous combined hormone replacement therapy has become available that contains estradiol and drospirenone as the progestogen component. Drospirenone is a synthetic progestogen, the only one in hormone replacement therapy in the UK that possesses clinically relevant anti-mineralocorticoid activity. The combination of estradiol and drospirenone has been shown to provide relief from estrogen-deficiency symptoms of the menopause. It also helps to prevent osteoporosis in postmenopausal women by increasing bone density. Further, it has been shown to provide protection against endometrial hyperplasia associated with unopposed estrogen therapy.

Risk of breast cancer during hormone replacement therapy: mechanisms

2010 ◽  
Vol 3 (1) ◽  
Author(s):  
Alfred O. Mueck ◽  
Harald Seeger ◽  
Samuel Shapiro
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Cancer Cells ◽  
Hormone Replacement ◽  
Estrogen Therapy ◽  
World Health ◽  
Breast Epithelial Cell ◽  
Increased Risk ◽  
Health Organization

AbstractRegarding estrogen replacement therapy, two main mechanisms have to be considered for it to be discussed as a potential carcinogen in the breast, and also considering the World Health Organization definition of estrogens and estrogen/progestogen combinations as “carcinogenic”: (i) the proliferative/apoptotic effects on already pre-existing estrogen-sensitive cancer cells and (ii) the production of possible genotoxic estrogen metabolites. By addition of the progestogen component, as is usual in non-hysterectomized women, both mechanisms can lead to an increased risk compared to estrogenonly therapy. The detailed mechanisms underlying the development of the benign breast epithelial cell into clinically relevant breast cancer cells are very complicated. Based on these mechanisms, the following simplified summary of the main steps explains that: (i) an increased risk cannot be excluded, (ii) especially when estrogens are combined with progestogens, but (iii) there are differences between the preparations used in therapy; (iv) the risk seems to be very rare, needing very special cellular and extracellular conditions, (v) and could even be decreased in special situations of estrogen therapy. It is concluded that when critically reviewed, an increased risk of breast cancer during hormone replacement therapy cannot be excluded in very rare cases. Definitive mechanistic evidence for a possible causal relationship with carcinogenesis still remains open.

Hormone replacement therapy: update and practical prescribing

2021 ◽  
Vol 2021 (10) ◽  
pp. 20-26
Author(s):  
Nikki Noble
Keyword(s):  
Hormone Replacement Therapy ◽  
Hormone Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement

Nikki Noble details what nurses need to know when advising patients on hormone therapy

Canine Alopecia Secondary to Human Topical Hormone Replacement Therapy in Six Dogs

2015 ◽  
Vol 51 (2) ◽  
pp. 136-142 ◽  
Author(s):  
Darren J. Berger ◽  
Thomas P. Lewis ◽  
Anthea E. Schick ◽  
Rose I. Miller ◽  
Diana G. Loeffler
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Clinical Signs ◽  
Hair Follicles ◽  
Normal Reference Range ◽  
Total Thyroxine ◽  
Histological Characteristics ◽  
Thoracic And Abdominal ◽  
Time To Onset

Alopecia is a common presenting complaint in veterinary medicine and is known to occur secondary to numerous primary conditions. In this report, six unrelated dogs from three households were subsequently determined to have developed alopecia as a result of accidental transdermal exposure to their owners' topical hormone replacement therapy (THRT). All cases presented with alopecia ranging in duration from 2 mo to 2.5 yr. All dogs demonstrated alopecia affecting the ventral neck, thoracic and abdominal surfaces, proximal lateral extremities, and lateral trunk. At the time of initial presentation, five of six dogs were also noted to have physical exam findings suggestive of feminization. In all cases, serum total thyroxine was within normal reference range. Affected skin was biopsied in five dogs, and all samples demonstrated four similar histological characteristics: basal melanosis, epidermal and infundibular follicular hyperkeratosis, kenogen hair follicles, and small sebaceous glands. All dogs had elevated baseline estradiol levels, and four dogs had concurrent elevations of baseline progesterone. Average time to onset of clinical signs in those dogs was 5.5 mo after the owners started THRT. Following discontinuation of THRT by the owners, all dogs had complete resolution of their clinical signs by 5.5 mo.

Sign in / Sign up

Export Citation Format

Share Document